History
The REPViT brand was created in 2020 to market and commercialise an innovative diagnostic platform for both virus and bacterial infections based on a proprietary IP (EP20382499.0).
The aim of REPViT is to offer fast, affordable and easy to use diagnostic solutions for consumers and professionals to detect SARS-CoV-2, Influenza and other viruses and bacteria at home and on the go, in less than 15 minutes using saliva.
The REPViT device concept is a rapid Nucleic Acid Test (NAT) equivalent to PCR in a single-use handheld over the counter test format, similar to a pregnancy test.
The company
The REPViT Solution
1) Scalability
The REPViT technology does not require any manufacturing that is not available at large scale (i.e. no electronics, microfluidics, optics etc), does not use enzymes and does not require large laboratory equipment or specialist staff. This allows for rapid mass production and deployment of the test to meet demand in order to contain even very virulent infections.
2) Flexibility
The REPViT technology is easy to use, not sensitive to temperature and can be prepared in a home-test kit format, applied in all geographies, and most circumstances such as work, school, transport, hospital, care home or football stadium. It can be adapted to detect additional virus based, or bacterial, infectious diseases.
3) Marketability
Due to the simplicity of handling and application of the REPViT test, it can be sold as a B2B product to doctors and hospitals or as B2C in form of a home-test kit through chemists or pharmacies and drugstores. Its comfortable application (using saliva from spitting and without intrusive nasal or buccal swabbing) will make it the preferred test.
4) Cost
The low production cost of the REPViT tests allows for the test to be used by all income levels and a number of tests can be used in sequence
5) Adaptability
The REPViT platform technology is easily adapted from the initial Covid-19/Influenza test and subsequently to other infectious diseases caused by viruses and bacteria.
This will allow governments, professionals and individuals to work together effectively to contain infectious diseases more efficiently and keep infection rates low.
The Team
The Team
Kevin Walker-Curran
Chief Executive Officer (CEO)
_____________________________________
Kevin has degrees in commerce and international finance and >30 years commercial experience as senior tax accountant for Deloitte and PWC, and project leader for Arthur Anderson and EY.
Operating at Senior Management level within several global financial organisations, Kevin has extensive experience in business development and operational management. With a focus on Project Management and process improvement, Kevin has worked across the world, at times managing up to 35 different country teams on multistate cross border projects.
The Team
The Team
The Team
Charles Lawrie
(DPhil, FRCPath)
Founder & Chief Scientific Officer (CSO)
_____________________________________
Charles did his doctorate from Institute of Virology (Oxford University), where he patented novel viral diagnostic technology for West Nile Virus. He later migrated to cancer research at John Radcliffe Hospital, Oxford. Author of >110 publications, he is a pioneer of biomarkers in bodily fluids.